THE ABILITIES OF A BISMUTH PREPARATION IN GASTROINTESTINAL DISEASES

Download full text PDF
Issue: 
7
Year: 
2016

Professor V. Tsukanov, MD; Professor E. Kasparov, MD; A. Vasyutin, Candidate of Medical Sciences; Yu. Tonkikh, Candidate of Medical Sciences Research Institute of Medical Problems of the North, Krasnoyarsk

The investigators studied the possibilities of using a bismuth preparation to eradicate Helicobacter pylori in 4-component regimens in order to heal gastroduodenal ulcerative defects, to protect the epithelium from progressive gastritis, and to treat diarrhea-predominant irritable bowel syndrome.
Keywords: 
gastroenterology
bismuth
Helicobacter pylori
peptic ulcer
functional dyspepsia
irritable bowel syndrome

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Hochradel J. Historiches zur Wismutfrace // Munch. Med. Wschr. – 1928; 1. 128: 177–81.
  2. DuPont H. Bismuth subsalicylate in the treatment and prevention of diarrheal disease // Drug Intell. Clin. Pharm. – 1987; 21 (9): 687–93.
  3. Graham D., Lee S. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly // Gastroenterol. Clin. North Am. – 2015; 44 (3): 537–63.
  4. Lambert J., Hansky J., Davidson A. et al. Campylobacter like organisms (CLO) in vivo and in vitro susceptibility to antimicrobial and antiulcer therapy // Gastroenterology. – 1985; 88: 1462.
  5. Borsch G., Graham D. Helicobacter pylori. Handbook of Experimental Pharmacology. Collen M.J., Benjamin S.B., editors. Pharmacology of peptic ulcer disease, vol.99 / Berlin: Springer-Verlag, 1991; p.107–48.
  6. Lambert J., Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection // Aliment. Pharmacol. Ther. – 1997; 11 (Suppl. 1): 27–33.
  7. Armstrong J., Wee S., Goodwin C. et al. Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro – an ultrastructural study // J. Med. Microbiol. – 1987; 24 (4): 343–50.
  8. Ge R., Sun X., Gu Q. et al. A proteomic approach for the identification of bismuth-binding proteins in Helicobacter pylori // J. Biol. Inorg. Chem. – 2007; 12 (6): 831–42.
  9. Borody T., Cole P., Noonan S. et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication // Med. J. Aust. – 1989; 151 (8): 431–5.
  10. Borody T., Andrews P., Fracchia G. et al. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori // Gut. – 1995; 37 (4): 477–81.
  11. de Boer W., Driessen W., Jansz A. et al. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection // Lancet. – 1995; 345 (8953): 817–20.
  12. Megraud F., Coenen S., Versporten A. et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption // Gut. – 2013; 62 (1): 34–42.
  13. Graham D., Hoffman J., el-Zimaity H. et al. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection // Aliment. Pharmacol. Ther. – 1997; 11 (5): 935–8.
  14. Dore M., Graham D., Mele R. et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection // Am. J. Gastroenterol. – 2002; 97 (4): 857–60.
  15. Zheng Q., Chen W., Lu H. et al. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance // J. Dig. Dis. – 2010; 11 (5): 313–8.
  16. Malfertheiner P., Megraud F., O’Morain C. et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report // Gut. – 2012; 61 (5): 646–64.
  17. Dore M., Lu H., Graham D. Role of bismuth in improving Helicobacter pylori eradication with triple therapy // Gut. – 2016; 65 (5): 870–8.
  18. Parente F., Maconi G., Bargiggia S. et al. Comparison of two lansoprazole antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients // Aliment. Pharmacol. Ther. – 1996; 10 (2): 211–3.
  19. Gisbert J., Romano M., Gravina A. et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments // Aliment. Pharmacol. Ther. – 2015; 41 (8): 768–75.
  20. Srinarong C., Siramolpiwat S., Wongcha-um A. et al. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand // Asian Pac. J. Cancer Prev. – 2014; 15 (22): 9909–13.
  21. Ergül B., Doan Z., Sarikaya M. et al. The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study // Helicobacter. – 2013; 18 (6): 454–8.
  22. Mu F., Hu F., Yang G. et al. Clinical Study of proton pump inhibitor- containing quadruple regimen as first-line therapy for Helicobacter pylori eradication // Chin. J. Gastroenterol. – 2007; 12: 531–4.
  23. Homeriki N.M., Homeriki S.G. Opyt primenenija chetyrehkomponent nyh lekarstvennyh shem, otlichnyh ot standartnoj kvadroterapii, pri leche-nii helikobakternoj infektsii // Ros. zhurn. gastroenterol., gepatol., kolo-proktol. – 2001; 2: 103.
  24. Yakovenko E., Grigoriev P., Yakovenko A. Bismuth-based regimes should be 24. first line therapy for Helicobacter pylori eradication // Gut. – 2002; 51 (S11): A92.
  25. Ivashkin V.T., Maev I.V., Lapina T.L. i dr. Rekomendatsii Rossijskoj Gastroenterologicheskoj Assotsiatsii po diagnostike i lecheniju infektsii Helicobacter pylori u vzroslyh // Ros. zhurn. gastroenterol., gepatol., koloprok-tol. – 2012; 1: 87–9.
  26. Coughlin G., Kupa A., Alp M. The effect of tri-potassium citrate bismuthate on healing of chronic duodenal ulcers // Med. J. Aust. – 1977; 1 (9): 294–8.
  27. Dekker W., Reisma K. Double-blind controlled trial with colloidal bismuth . subcitrate in the treatment of symptomatic duodenal ulcers with special references to blood and urine bismuth levels // Ann. Clin. Res. – 1979; 11 (3): 94–7
  28. Wilson P., Alp M. Colloidal bismuth subcitrate tablets and placebo in chronic duodenal ulceration: a double-blind, randomised trial // Med. J. Aust. – 1982; 1 (5): 222–3.
  29. Tytgat G. Colloidal bismuth subcitrate in peptic ulcer – a review // Digestion. – 1987; 37 (Suppl. 2): 31–41.
  30. Sutton D. Gastric ulcer healing with tripotassium dicitrato bismuthate and subsequent relapse // Gut. – 1982; 23 (7): 621–4.
  31. Tytgat G., Can Bentam N., Van Olffen G. et al. Controlled trial comparing colloidal bismuth subcitrate tablets, cimetidine and placebo in the treatment of gastric ulceration // Scand. J. Gastroenterol. – 1982; 17: 31–8.
  32. Karateev A.E., Nasonov E.L., Radenska-Lopovok S.G. Effektivnost' vismuta trikalija ditsitrata (de-nola) pri gastropatijah, indutsirovannyh nesteroidnymi pro tivovospalitel'nymi preparatami: otkrytoe kontroli-ruemoe 4-nedel'noe issledovanie // Ter. arh. – 2005; 2: 45–9.
  33. Maev I.V., V'juchnova E.S., Staseva I.V. Sravnitel'naja otsenka razlich nyh shem terapii gastropatij, vyzvannyh nesteroidnymi protivovospali-tel'nymi preparatami // Ter. arh. – 2004; 2: 27–30.
  34. Karateev A.E., Uspenskij Ju.P., Pahomova I.G. i dr. Kombinirovannoe lechenie jazv zheludka, indutsirovannyh nesteroidnymi protivovospalitel'-nymi preparatami. Rezul'taty 4-nedel'nogo otkrytogo kontroliruemogo issledovanija po otsenke effektivnosti kombinatsii ingibitora protonnogo nasosa i vismuta trikalija ditsitrata // Ter. arh. – 2009; 6: 62–7.
  35. Lee S. A potential mechanism of action of colloidal bismuth subcitrate: diffusion barrier to hydrochloric acid // Scand. J. Gastroenterol. Suppl. – 1982; 80: 17–21.
  36. Tasman-Jones C., Maher C., Thomsen L. et al. Mucosal defences and gastroduodenal disease // Digestion. – 1987; 37 (Suppl. 2): 1–7.
  37. Hollanders D., Morrissey S., Mehta J. Mucus secretion in gastric ulcer patients treated with tripotassiumdicitratobismuthate (De-Nol) // Br. J. Clin. Pract. – 1983; 37 (3): 112–4.
  38. Konturek S., Radecki T., Piastucki I. et al. Gastrocytoprotection by colloidal 38. bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins // Gut. – 1987; 28 (2): 201–5.
  39. Konturek S., Radecki T., Piastucki I. et al. Advances in the understanding of 39. the mechanism of cytoprotective action by colloidal bismuth subcitrate // Scand. J. Gastroenterol. Suppl. – 1986; 122: 6–10.
  40. Konturek S., Bilski J., Kwiecien N. et al. De-Nol stimulates gastric and 40. duodenal alkaline secretion through prostaglandin dependent mechanism // Gut. – 1987; 28 (12): 1557–63.
  41. Baron J., Barr J., Batten J. Acid, pepsin, and mucus secretion in patients 41. with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol) // Gut. – 1986; 27 (5): 486–90.
  42. Sheptulin A.A., Vize-Hripunova M.A. Sovremennye vozmozhnosti pri-42. menenija preparatov vismuta v gastroenterologii // Ros. zhurn. gastroente-rol., gepatol., koloproktol. – 2010; 3: 63–7.
  43. Gorbach S. Bismuth therapy in gastrointestinal diseases // 43. Gastroenterology. – 1990; 99 (3): 863–75.
  44. Severi C., Abdullahi M., Tari R. et al. High efficacy of bismuth subcitrate for 44. Helicobacter pylori eradication in pangastritis // Dig. Liver Dis. – 2009; 41 (8): 555–8.
  45. Rokkas T., Pursey C., Uzoechina E. et al. Non-ulcer dyspepsia and short 45. term De-Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori // Gut. – 1988; 29 (10): 1386–91.
  46. Stanghellini V., Chan F., Hasler W. Gastroduodenal Disorders // 46. Gastroenterology. – 2016; 150 (6): 1380–92.
  47. Butorin N.N., Bichurina T.B., Tsukanov V.V. i dr. Rasprostranennost' i 47. klinicheskie aspekty pischevoda Barretta u naselenija Vostochnoj Sibiri // Ter. arh. – 2013; 1: 62–5.
  48. Tsukanov V.V., Tret'jakova O.V., Amel'chugova O.S. i dr. Rasprostranennost' 48. atroficheskogo gastrita tela zheludka u naselenija g. Krasnojarska starshe 45 let // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 2012; 4: 27–31
  49. Bagchi D., McGinn T., Ye X. et al. Mechanism of gastroprotection by 49. bismuth subsalicylate against chemically induced oxidative stress in cultured human gastric mucosal cells // Dig. Dis. Sci. – 1997; 42 (9): 1890–900.
  50. Turkez H., Geyikoglu F. The efficiacy of bismuth subnitrate against 50. genotoxicity and oxidative stress induced by aluminum sulphate // Toxicol. Ind. Health. – 2011; 27 (2): 133–42.
  51. Kononov A.V. Tsitoprotektsija slizistoj obolochki zheludka: 51. molekuljarno-kletochnye mehanizmy // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 2006; 3: 12–6.
  52. Rugge M., Correa P., Di Mario F. et al. OLGA staging for gastritis: a tutorial 52. // Dig Liver Dis. – 2008; 40 (8): 650–8
  53. Kononov A.V., Mozgovoj S.I., Rybkina L.B. Otsenka tsitoprotektivnogo 53. vlijanija vismuta trikalija ditsitrata na slizistuju obolochku zheludka pri eradikatsii H. pylori i prolongirovannom prieme preparata // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 2014; 6: 21–8.
  54. DuPont H., Sullivan P., Pickering L. et al. Symptomatic treatment of 54. diarrhea with bismuth subsalicylate among students attending a Mexican university // Gastroenterology. – 1977; 73 (4 Pt. 1): 715–8.
  55. Osipenko M.F., Bikbulatova E.A. Sindrom diarei i preparaty vismu-55. ta // Effektivnaja farmakoterapija v gastroenterologii. – 2008; 1: 42–7.
  56. Parfenov A.I., Ruchkina I.N., Osipov G.A. Vismuta trikalija ditsitrat 56. v lechenii bol'nyh postinfektsionnym SRK s preobladaniem diarei // Rus. med. zhurn. – 2006; 2: 3–6.
  57. Jakovenko E.P., Agafonova N.A., Pohal'skaja O.Ju. i dr. Primenenie 57. vismuta trikalija ditsitrata (de-nola) – perspektivnoe napravlenie v patoge-neticheskoj terapii sindroma razdrazhennogo kishechnika s diareej // Klin. med. – 2008; 10: 47–52.